magi east 2016 w870 - nolen (edits v3.0)
TRANSCRIPT
![Page 1: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/1.jpg)
Commercialization of an IRB
Workshop W870 IRB Best PracticesMAGI East 2016
Parker Nolen, MBA, CCRC, CIPDirector
Research Compliance & Regulatory AffairsCommunity Health Network
![Page 2: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/2.jpg)
Identify Market Consolidation
Implications for the Local IRB
Understand Basic Concepts of Management Theory
Identify SWOT
Identify a Local IRB’s Built-in Advantages
Cost Analysis Case Study
Understand Net Present Value Concepts
Objectives
![Page 3: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/3.jpg)
3
I am from a
A. Hospital-based IRB
B. Medical Academic Center IRB
C. Commercial IRB
D. Sponsor
Polling Question
![Page 4: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/4.jpg)
Then…
![Page 5: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/5.jpg)
5
Now…
![Page 6: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/6.jpg)
6
...Nearly 200 airports, most of them tiny and many in remote places, have lost air service entirely since 2008....Airlines have made a deliberate decision to forgo certain markets...Their new business model is leaving communities disenfranchised and disconnected from the global marketplace.
(Mouad, Jad. "Lost Jobs, Lost Flights." New York Times 09 July 2011)
Result of airline consolidation
![Page 7: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/7.jpg)
7
What do we do?
![Page 8: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/8.jpg)
8
2016
![Page 9: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/9.jpg)
9
20XX
![Page 10: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/10.jpg)
10
Implications for Local IRBs
• Will Local IRBs have relevance?• Will the field remain “Professional”?• Will we have access to Sponsored research?• Will our patients have access to novel points of care?
Yes! But…
Local IRBs must be strategic in their thinking and creative in approaching their operations and their cost/revenue analysis…
![Page 11: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/11.jpg)
11
• IRB consolidation will continue into “2nd Tier”
• SOME form of the Single IRB Review will survive from NPRM
• IRB Segment of will de-stabilize in 24-36 months• Institutionally-based IRBs will commercialize to ensure access
to sponsored research• New Revenue models will emerge• New Partnerships will emerge
• May be some interest from DOJ regarding anti-trust in the commercial IRB sector
Industry Forecast (Private Sector)
![Page 12: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/12.jpg)
12
SWOT Analysis
![Page 13: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/13.jpg)
13
• Figure out what your IRB wants to be• Porter’s Three Strategies
• Figure out how to do it• Strategy vs. Tactic
• Develop a relationship with Finance• Identify your Competitive Advantage• Calculate your Net Present Value (NPV)
Addressing the SWOT
![Page 14: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/14.jpg)
14
Porter’s Three Strategies
Cost Leadership Differentiation
Niche (Focus)
Stuck in the Middle
![Page 15: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/15.jpg)
15
• Know what your product costs!• How much does it cost to run a meeting?• How are our overhead costs allocated in the
organization?• Can they be shared across a wide population/large
number of regions or departments?• Develop a close relationship with Finance
Department
Quick note about Financials…
![Page 16: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/16.jpg)
16
Polling Question
I know how much it costs to run my IRB meeting.
A. Yes
B. No
![Page 17: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/17.jpg)
17
• It is exactly what it sounds like
• The low-cost leader in any market gains competitive advantage from being able to produce the product/service at the lowest cost.
• This is an easy strategy that can be leveraged by Local IRBs!
Cost Leadership
![Page 18: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/18.jpg)
18
• Allows companies to charge high process and focus on a volume that generates a better margin.
• This will incur additional costs in creating the competitive advantage.
• Example: Creating an oncology-only IRB
Differentiation
![Page 19: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/19.jpg)
19
• Identifiable and unique needs• Sufficient size
• Difficult, but doable!
Niche (Focus)
![Page 20: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/20.jpg)
20
• Identify capability in which your IRB excels.• Focus on opportunities in that area, letting others
go.• This capability is difficult for others to duplicate.
• Involves the skill and coordination of people across a variety of functional areas or processes used to deliver value to the customer.
Core Competency
![Page 21: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/21.jpg)
21
Strategy vs. Tactic
Strategy• Is the “What”• Defines goals• Larger plan made up of
several tactics
• Example:• Make our Local IRB
desirable for Sponsors to use by offering multi-site approvals
Tactic• Is the “How”• Specific actions• Implements the strategy
• Example:• Aligning with another
Local IRB through merger or reciprocal agreement
![Page 22: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/22.jpg)
Put another way:
Source: http://www.uxmatters.com/mt/archives/2015/02/strategy-versus-tactics.php
![Page 23: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/23.jpg)
23
Polling Question
A capability in which you excel and is difficult for others to duplicate is a:
A. Cost Leadership Strategy
B. Tactic
C. Core Competency
D. Niche (focus) Strategy
![Page 24: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/24.jpg)
24
• How much does it cost to run a meeting?• How are our overhead costs allocated in the
organization?• Can they be shared across a wide region/number of
departments?• What are we doing that does not need to be done?
Things to Immediately Understand
![Page 25: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/25.jpg)
25
• Cost and Overhead Allocation• Work with Finance people to spread costs over
the entire institution/network as a shared service.• May not be possible, but if you are a multi-site IRB, it is
probable.• Not an easy argument – Be Prepared!
• Marginal Costs are Low• Allows for innovative pricing/revenue
management strategies.
Local IRB’s Built-in Advantages:
![Page 26: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/26.jpg)
26
• Scenario # 1 – Outsource ALL IRB functions
• Scenario #2 – Create a Revenue Stream/Cost Offset (Commercialize)
• Actual Bid Details:• $326,000 per year • $50,000 transfer cost (one-time charge)• Expedited/Exempt studies will be billed to the hospital,
with $0 revenue back to the hospital for industry trials• Steady state of 150 protocols
Cost Analysis Case Study
![Page 27: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/27.jpg)
27
NPV Definition and Formula
“r” represents the rate of return. It is determined by industry and usually ranges from 8% – 15%.
![Page 28: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/28.jpg)
28
• Bid Details:• $326,000 Annual
Operational Cost• $50,000 Transfer Cost• Expedited/Exempt
Studies billed to hospital• 1 FTE @ $50,000
Scenario #1 – Outsource Completely
Completely outsourcing would be an expense of $1.6M! And this does not include the additional $2M malpractice insurance required by the central IRB.
![Page 29: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/29.jpg)
29
Yearly Interst Rate 2.00%Cost of Investment ($710,048)
2015 Revenue $18,000 $7,500 $180,0002016 Revenue $30,000 $12,500 $300,0002017 Revenue $42,000 $17,500 $420,0002018 Revenue $69,000 $22,500 $540,000
NPV ($560,243) $766,693 $2,069,521
SoftwareLease Cost per month $626 Initial Review $1,000Annual Lease $30,048Salaries* $130,000 $520,000 Renewals $500Fringe $156,000 Supplies $1,000 $4,000 Amendments $250
Cost of Investment $710,048
Cost of Investment over 4 Year Period Fees
Assumptions:• 1 New Protocol per Month• $1000 - Initial Review• $500 - Renewals• $250 - Amendments• 0 Renewals Year 1• 2 Amendments per protocol
per year• 2 FTE @ $130,000• Software Lease
Scenario # 2 – Create a Revenue Stream
Keeping the IRB functions in-house and creating a revenue stream has AVOIDED an additional expense of $907,952 over the four-year period
![Page 30: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/30.jpg)
30
• Sponsor buy-in• Accreditation• 501(c)3 (non-profit) status justification• Benefit for the community• Not profit-driven – this is a cost-offset model
Obstacles
NOTE: Local IRBs are NOT sitting on a hidden Gold Mine…
You will be a revenue-positive cost-offset - ONLY
![Page 31: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/31.jpg)
31
2013
Snapshot
2016
![Page 32: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/32.jpg)
32
Conclusion
• Keep abreast of industry trends• Know your SWOT• Identify your Core Competencies• Identify your Competitive Advantages• Identify your costs/potential revenue• Build a relationship with Finance• Consider Alternative Models
![Page 33: MAGI East 2016 W870 - Nolen (edits v3.0)](https://reader035.vdocuments.us/reader035/viewer/2022062515/58ea783b1a28ab0c0b8b4f7d/html5/thumbnails/33.jpg)
33
Contact Information
Parker Nolen, MBA, CCRC, CIPDirectorResearch Compliance and Regulatory Affairs
(317) 355-5678